Ab&b Biotechnology

Taizhou, China Founded: 2015 • Age: 11 yrs
Quadrivalent influenza vaccines are developed using proprietary subunit technology.

About Ab&b Biotechnology

Ab&b Biotechnology is a company based in Taizhou (China) founded in 2015.. Ab&b Biotechnology has raised $92.76 million across 1 funding round from investors including Green Pine Capital Partners, Yingke Capital and Honghui Fund. Ab&b Biotechnology operates in a competitive market with competitors including Adaptive Biotechnologies, Moderna, Serum Institute of India, Vaxcyte and Generate Biomedicines, among others.

  • Headquarter Taizhou, China
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Legal Name Ab&B Bio-Tech Co., Ltd. Js Class H
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $92.76 M (USD)

    in 1 rounds

  • Latest Funding Round
    $92.76 M (USD), Series C

    Aug 04, 2021

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Ab&b Biotechnology

Ab&b Biotechnology is a publicly listed company on the HKEX with ticker symbol 2627 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: HKEX · Ticker: 2627 . Sector: Health technology · Hong Kong

Funding Insights of Ab&b Biotechnology

Ab&b Biotechnology has successfully raised a total of $92.76M through 1 strategic funding round. The most recent funding activity was a Series C round of $92.76 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series C — $92.8M
  • First Round

    (04 Aug 2021)

  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Aug, 2021 Amount Series C - Ab&b Biotechnology Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Ab&b Biotechnology

Ab&b Biotechnology has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Green Pine Capital Partners, Yingke Capital and Honghui Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Early- and growth-stage investments are directed toward hard technology sectors.
Founded Year Domain Location
Healthcare startups are funded by HLC venture capital firm.
Founded Year Domain Location
Venture capital firm investing in tech sectors
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Ab&b Biotechnology

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Abb Biotechnology

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Ab&B Biotechnology Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Ab&b Biotechnology

Ab&b Biotechnology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adaptive Biotechnologies, Moderna, Serum Institute of India, Vaxcyte and Generate Biomedicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Clinical diagnostics and drug discovery for immune diseases are provided.
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
domain founded_year HQ Location
Vaccines for infectious diseases are developed using cell-free protein synthesis.
domain founded_year HQ Location
Developer of novel protein-based therapeutics using machine learning and biological engineering
domain founded_year HQ Location
Developer of immunotherapies for the treatment of infectious diseases and cancer
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Ab&B Biotechnology

Frequently Asked Questions about Ab&b Biotechnology

When was Ab&b Biotechnology founded?

Ab&b Biotechnology was founded in 2015 and raised its 1st funding round 6 years after it was founded.

Where is Ab&b Biotechnology located?

Ab&b Biotechnology is headquartered in Taizhou, China. It is registered at Taizhou, Jiangsu, China.

Is Ab&b Biotechnology a funded company?

Ab&b Biotechnology is a funded company, having raised a total of $92.76M across 1 funding round to date. The company's 1st funding round was a Series C of $92.76M, raised on Aug 04, 2021.

What does Ab&b Biotechnology do?

Founded in 2015 and based in Taizhou, China, the biotechnology company focuses on vaccine development within the healthcare sector. Proprietary technology is employed to create a quadrivalent subunit vaccine targeting four influenza virus strains. Operations center on research and production of influenza protections, with emphasis on efficacy against seasonal variants. The domain abbbio.com supports company information and outreach.

Who are the top competitors of Ab&b Biotechnology?

Ab&b Biotechnology's top competitors include Moderna, Adaptive Biotechnologies and Vaxcyte.

Is Ab&b Biotechnology publicly traded?

Yes, Ab&b Biotechnology is publicly traded on HKEX under the ticker symbol 2627.

Who are Ab&b Biotechnology's investors?

Ab&b Biotechnology has 4 investors. Key investors include Green Pine Capital Partners, Yingke Capital, Honghui Fund, and Guohai Innovation Capital Investment Management.

What is Ab&b Biotechnology's ticker symbol?

The ticker symbol of Ab&b Biotechnology is 2627 on HKEX.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available